CLINICAL TRIALS PROFILE FOR VISKEN
✉ Email this page to a colleague
All Clinical Trials for VISKEN
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00424801 ↗ | Effects of Intensive Long-Term Vasodilation in Hypertensive Patients With Microvascular Angina Pectoris | Terminated | Danish Cardiovascular Research Academy | N/A | 2007-01-01 | The purpose of this study is to determine if long-term vasodilatory treatment is more effective than the standard treatment in hypertensive patients with microvascular angina pectoris |
| NCT00424801 ↗ | Effects of Intensive Long-Term Vasodilation in Hypertensive Patients With Microvascular Angina Pectoris | Terminated | Danish Heart Foundation | N/A | 2007-01-01 | The purpose of this study is to determine if long-term vasodilatory treatment is more effective than the standard treatment in hypertensive patients with microvascular angina pectoris |
| NCT00424801 ↗ | Effects of Intensive Long-Term Vasodilation in Hypertensive Patients With Microvascular Angina Pectoris | Terminated | Novartis | N/A | 2007-01-01 | The purpose of this study is to determine if long-term vasodilatory treatment is more effective than the standard treatment in hypertensive patients with microvascular angina pectoris |
| NCT00424801 ↗ | Effects of Intensive Long-Term Vasodilation in Hypertensive Patients With Microvascular Angina Pectoris | Terminated | University of Aarhus | N/A | 2007-01-01 | The purpose of this study is to determine if long-term vasodilatory treatment is more effective than the standard treatment in hypertensive patients with microvascular angina pectoris |
| NCT01400165 ↗ | Comparison of the Pharmacokinetics of Three Generic Medications and Their Respective Brand Preparations | Unknown status | University of Ottawa | Phase 1 | 2011-07-01 | Generic describes a pharmaceutical product that does not have a brand name or trademark. Generic medications should be the equivalent of brand medications. Only their price should be different. The active ingredient of the generic medication has to be within a window of 80 to 125% of the original in the blood. There are reports that this standard is not always followed after the medication has been on the market. Indeed, it was observed that some patients previously stable on original medications relapsed when switched to a generic. Several factors could account for this problem. Such problems have been reported for Pindolol, Quetiapine, and Trazodone. Some properties of specific brands of the generics and the original brands will be examined for these three medications. The three original medications used in this study are the Visken, the Seroquel, and the Desyrel. The three generics are the Teva-pindolol, the Teva-Quetiapine, and the Teva-Trazodone. They are all available on the Canadian market by prescription. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for VISKEN
Condition Name
Clinical Trial Locations for VISKEN
Clinical Trial Progress for VISKEN
Clinical Trial Phase
Clinical Trial Sponsors for VISKEN
Sponsor Name
